Cargando…
Oncolytic Adenoviruses in Cancer Treatment
The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to rep...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423481/ https://www.ncbi.nlm.nih.gov/pubmed/28548059 http://dx.doi.org/10.3390/biomedicines2010036 |
_version_ | 1783234954826612736 |
---|---|
author | Alemany, Ramon |
author_facet | Alemany, Ramon |
author_sort | Alemany, Ramon |
collection | PubMed |
description | The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to replicate selectively in tumor cells have been clinically tested by intratumoral or systemic administration. Limited efficacy has been associated to poor tumor targeting, intratumoral spread, and virocentric immune responses. A deeper understanding of these three barriers will be required to design more effective oncolytic adenoviruses that, alone or combined with chemotherapy or immunotherapy, may become tools for oncologists. |
format | Online Article Text |
id | pubmed-5423481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54234812017-05-23 Oncolytic Adenoviruses in Cancer Treatment Alemany, Ramon Biomedicines Review The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to replicate selectively in tumor cells have been clinically tested by intratumoral or systemic administration. Limited efficacy has been associated to poor tumor targeting, intratumoral spread, and virocentric immune responses. A deeper understanding of these three barriers will be required to design more effective oncolytic adenoviruses that, alone or combined with chemotherapy or immunotherapy, may become tools for oncologists. MDPI 2014-02-21 /pmc/articles/PMC5423481/ /pubmed/28548059 http://dx.doi.org/10.3390/biomedicines2010036 Text en © 2014 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Alemany, Ramon Oncolytic Adenoviruses in Cancer Treatment |
title | Oncolytic Adenoviruses in Cancer Treatment |
title_full | Oncolytic Adenoviruses in Cancer Treatment |
title_fullStr | Oncolytic Adenoviruses in Cancer Treatment |
title_full_unstemmed | Oncolytic Adenoviruses in Cancer Treatment |
title_short | Oncolytic Adenoviruses in Cancer Treatment |
title_sort | oncolytic adenoviruses in cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423481/ https://www.ncbi.nlm.nih.gov/pubmed/28548059 http://dx.doi.org/10.3390/biomedicines2010036 |
work_keys_str_mv | AT alemanyramon oncolyticadenovirusesincancertreatment |